The Study of Marketed and Experimental Formulation Approaches Enabling Site-specific Delivery of Mesalamine in Patients with Inflammatory Bowel Disease

Title:The Study of Marketed and Experimental Formulation Approaches Enabling Site-specific Delivery of Mesalamine in Patients with Inflammatory Bowel Disease

Volume: 8 Issue: 1

Author(s): Irina Kadiyala and Dylan Jacobs

Affiliation:

Keywords: Apriso, asacol, asacol HD, 5-ASA, Crohn’s disease and ulcerative colitis, inflammatory bowel disease, lialda, mesalamine, oral delivery, pentasa.

Abstract: This patent review focuses exclusively on the oral delivery of mesalamine (5-ASA) and excludes oral mesalamine pro-drug and rectal delivery formulations. The formulation strategies of marketed formulations (Apriso®, Asacol®, Lialda® and Pentasa®) and non-marketed formulations are reviewed and explained by decoding formulation specifics that enable the site specific delivery for the treatment of inflammatory bowel disease.

Cite this article as:

Kadiyala Irina and Jacobs Dylan, The Study of Marketed and Experimental Formulation Approaches Enabling Site-specific Delivery of Mesalamine in Patients with Inflammatory Bowel Disease, Recent Patents on Drug Delivery & Formulation 2014; 8 (1) . https://dx.doi.org/10.2174/18722113113079990014